 |
BioWorld-International-2005-02-02
Genzyme Sues To Halt TKT's Gaucher's Program In Israel
CAT Gaining Cash Via High Court Decision; Abbott Can Seek Appeal
LONDON - Cambridge Antibody Technology (CAT) Group plc received about £13.4 million (US$25 million) from Abbott Laboratories after the pharmaceutical company wasn't able to appeal a High Court judgment in CAT's favor and ordered to pay royalty arrears on sales of the blockbuster rheumatoid arthritis drug Humira. (BioWorld International)